Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences, Inc.

SOLANA BEACH, CALIF., AUG. 13, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY PROVIDED A BUSINESS UPDATE AND ANNOUNCED ITS FINANCIAL AND OPERATIONAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025.

ARTELO BIOSCIENCES PROVIDES BUSINESS UPDATE ANDREPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

EXTENDS PATENT PROTECTION THROUGH DECEMBER 2041 ART27.13 IS CURRENTLY UNDER EVALUATION IN A PHASE 2 STUDY FOR THE TREATMENT OF CANCER-RELATED ANOREXIA SOLANA BEACH, CALIF., AUG. 11, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THAT THE EUROPEAN PATENT OFFICE (EPO) HAS ISSUED A NOTICE OF ALLOWANCE FOR ARTELO'S EUROPEAN PATENT APPLICATION NO.

ARTELO BIOSCIENCES RECEIVES NOTICE OF ALLOWANCE FROM EUROPEAN PATENT OFFICE FOR THE PATENT CLAIMS FOR THE INTENDED COMMERCIAL FORMULATION OF ART27.13

LEAD INVESTOR BARTOSZ LIPISKI, PREVIOUSLY HEAD OF ENGINEERING AT SOLANA LABS, WILL SERVE AS A TECHNICAL PARTNER CUBE SELECTED TO SECURE STORAGE, STAKING, AND ACTIVE DEFI EXECUTION OF ARTELO'S DIGITAL ASSET TREASURY ARTELO'S BOARD APPROVES AUTHORIZATION TO EXPAND COMPANY'S SOL TREASURY MANAGEMENT STRATEGY OVER TIME SOLANA BEACH, CALIF., AUG. 04, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR AN AT-THE MARKET PIPE (PRIVATE INVESTMENT IN PUBLIC EQUITY) FOR THE PURCHASE AND SALE OF SECURITIES AT A PRICE OF$10.45, CONSISTING OF: (A) 906,687 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF); (B) THREE-YEAR WARRANTS TO PURCHASE 906,687 SHARES OF COMMON STOCK AT AN EXERCISE PRICE OF $10.20 PER SHARE; AND (C) THREE-YEAR WARRANTS TO PURCHASE 906,687 SHARES OF COMMON STOCK AT AN EXERCISE PRICE OF $50.00 PER SHARE, FOR EXPECTED AGGREGATE GROSS PROCEEDS OF APPROXIMATELY$9.475 MILLION.

ARTELO BIOSCIENCES ANNOUNCES $9.475 MILLION AT-THE-MARKET PRIVATE PLACEMENT TO INITIATE SOLANA TREASURY STRATEGY, BECOMING FIRST PUBLICLY-TRADED PHARMACEUTICAL COMPANY TO ADOPT SOL AS A CORE RESERVE ASSET

MHRA INDICATED ART12.11 MAY BE A CANDIDATE FOR ACCELERATED DEVELOPMENT VIA THE INNOVATIVE LICENSING AND ACCESS PATHWAY MHRA INDICATED ART12.11 MAY BE A CANDIDATE FOR ACCELERATED DEVELOPMENT VIA THE INNOVATIVE LICENSING AND ACCESS PATHWAY

ARTELO BIOSCIENCES RECEIVES FAVORABLE UK MHRA GUIDANCE FOR A PHASE 1 TRIAL OF ART12.11, THE COMPANY'S PROPRIETARY CBD:TMP COCRYSTAL BEING DEVELOPED FOR THE TREATMENT OF ANXIETY AND DEPRESSION

ART26.12, A NOVEL FABP5 INHIBITOR, DEMONSTRATES SUSTAINED ANALGESIC EFFECTS WITHOUT TOLERANCE ART26.12, A NOVEL FABP5 INHIBITOR, DEMONSTRATES SUSTAINED ANALGESIC EFFECTS WITHOUT TOLERANCE

ARTELO BIOSCIENCES ANNOUNCES POSITIVE PRECLINICAL EFFICACY DATA FOR ART26.12 IN OSTEOARTHRITIS PAIN AT THE 35TH ANNUAL INTERNATIONAL CANNABINOID RESEARCH SOCIETY SYMPOSIUM

ART12.11, THE PATENTED CBD:TMP COCRYSTAL, DEMONSTRATES POTENT ANTIDEPRESSANT-LIKE ACTIVITY AND COGNITIVE BENEFITS OVER LEADING SSRI

ARTELO BIOSCIENCES ANNOUNCES POSITIVE PRECLINICAL EFFICACY WITH ART12.11 IN STRESS-INDUCED DEPRESSION MODEL

FIRST ORALLY ACTIVE FATTY ACID BINDING PROTEIN 5 INHIBITOR EVALUATED IN HUMANS FIRST-IN-CLASS APPROACH TARGETS UNMET NEED IN MULTIBILLION-DOLLAR PAIN MANAGEMENT MARKET SOLANA BEACH, CALIF., JUNE 30, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED FAVORABLE RESULTS FROM ITS FIRST-IN-HUMAN STUDY EVALUATING ART26.12, A NOVEL INHIBITOR OF FATTY ACID BINDING PROTEIN 5 (FABP5).

ARTELO BIOSCIENCES ANNOUNCES POSITIVE FIRST-IN-HUMAN DATA FOR ART26.12, A NOVEL NON-OPIOID TREATMENT CANDIDATE FOR PERSISTENT PAIN

SOLANA BEACH, CALIF., JUNE 26, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED IT HAS ENTERED INTO A DEFINITIVE SECURITIES PURCHASE AGREEMENT FOR AN AT-THE-MARKET PRIVATE PLACEMENT FOR GROSS PROCEEDS OF APPROXIMATELY $1.425 MILLION.

ARTELO BIOSCIENCES ANNOUNCES $1.425 MILLION AT-THE-MARKET PRIVATE PLACEMENT FINANCING

SOLANA BEACH, CALIF., JUNE 11, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THAT ON MAY 20, 2025 ARTELO'S BOARD OF DIRECTORS APPROVED A 6-FOR-1 REVERSE STOCK SPLIT (REVERSE SPLIT) OF THE COMPANY'S COMMON STOCK (COMMON STOCK).

ARTELO BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT

SOLANA BEACH, CALIF., JUNE 05, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED ITS PRESENTATION OF NEW DATA AT THE BRITISH PAIN CONFERENCE HELD IN NEWPORT, WALES, UK ON JUNE 3-5, 2025 (HTTPS://BPSASM.ORG/) THAT FURTHER VALIDATES THE THERAPEUTIC POTENTIAL OF FATTY ACID BINDING PROTEIN (FABP) INHIBITORS IN TREATING OSTEOARTHRITIS (OA) PAIN.

ARTELO'S FATTY ACID BINDING PROTEIN 5 INHIBITOR, ART26.12, COMPARES FAVORABLY TO NAPROXEN IN AN OSTEOARTHRITIS PAINSTUDY

SOLANA BEACH, CALIF., JUNE 02, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL OR NEUROLOGICAL CONDITIONS, TODAY WELCOMED THE PUBLICATION OF A COMPREHENSIVE REVIEW IN NEUROBIOLOGY OF DISEASE, TITLED FATTY ACID BINDING PROTEINS AND THEIR INVOLVEMENT IN ANXIETY AND MOOD DISORDERS, THAT UNDERSCORES THE THERAPEUTIC POTENTIAL OF FATTY ACID BINDING PROTEIN (FABP) INHIBITORS IN TREATING MOOD AND ANXIETY DISORDERS.

NEW INDEPENDENT REVIEW PAPER STRENGTHENS THERAPEUTIC RATIONALE FOR ARTELO'S FABP INHIBITOR PROGRAM IN ANXIETY AND DEPRESSION

ART26.12 PHASE 1 IN HEALTHY VOLUNTEERS COMPLETES ENROLLMENTWITH CLINICAL DATA ANNOUNCEMENT EXPECTED THIS QUARTER ART26.12 PHASE 1 IN HEALTHY VOLUNTEERS COMPLETES ENROLLMENTWITH CLINICAL DATA ANNOUNCEMENT EXPECTED THIS QUARTER

Artelo Biosciences, Inc.

ARTL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Artelo Biosciences, Inc.

ARTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ARTL